Albany, NY, United States
Albany, NY, United States

Time filter

Source Type

News Article | May 10, 2017
Site: www.businesswire.com

KEARNEY, Neb.--(BUSINESS WIRE)--SCORR Marketing, a global health science marketing and communications firm, is excited to announce that Krystle Buntemeyer, senior vice president and chief marketing officer, was named the 2017 Marketer of the Year by the American Marketing Association – Omaha at the Pinnacle Awards Show. The Marketer of the Year Award is considered the highest honor and is only awarded to one individual per year. “I’m extremely proud of all that Krystle has accomplished professionally and for our clients,” said Cinda Orr, president and CEO. “She has been instrumental in building SCORR and it has been a pleasure to watch her grow into a health science industry leader.” In addition to Buntemeyer’s award, SCORR won Pinnacle awards, the AMA’s highest honor, for Buffalo Roofing’s television commercial and SCORR’s own 2016 holiday gifts and branded packaging that SCORR presented to clients during the holiday season. SCORR was also recognized by the American Marketing Association – Lincoln with three awards including: Prism awards for its corporate branding campaign for Cryoport and downtown ad banners for the City of Kearney, and merit awards for its Cryoport case studies and its booth design for endpoint for the Drug Information Association Annual Meeting. At the Healthcare Advertising Awards, SCORR received gold awards for endpoint’s DIA booth design and WellSpring’s trade show giveaways, a silver award for the Chiltern website, a bronze for AMRI’s CPhI trade show booth, as well as merit awards for Chiltern HR recruitment videos and the Chiltern brochure system. In this year’s Aster Awards, SCORR received gold awards for the Chiltern brochure system and HR recruitment videos, Cryoport’s case studies, LabConnect’s 3D Lego mailer and WellSpring’s giveaways, plus a silver award for AMRI’s CPhI trade show booth. To learn more about SCORR’s award-winning capabilities, visit scorrmarketing.com. About SCORR Marketing SCORR Marketing is the leading marketing and communications firm in the health sciences industry. We partner with organizations involved in global research, development and commercialization of biopharmaceutical and device products and the delivery of health care products and services. At SCORR, we achieve results for our clients by applying our proven, disciplined approach to synthesize market intelligence, strategy and creativity. We have locations across North America and Europe. For more information, visit www.scorrmarketing.com.


News Article | May 9, 2017
Site: www.prnewswire.co.uk

Non-GAAP net income, non-GAAP diluted EPS and adjusted EBITDA are non-GAAP financial measures. For a discussion of these measures and reconciliations to U.S. GAAP measures, see "Non-GAAP Financial Measures" and Tables 1, 2 and 3. "We delivered an excellent first quarter, driven by 56 percent growth in contract revenue, 7 percent on an organic basis, including double digit organic growth in our Discovery, Development and Analytical Services (DDS) and Active Pharmaceutical Ingredient (API) businesses," said William S. Marth, AMRI's president and chief executive officer. "GAAP income from operations increased $6 million, a 150% increase quarter over quarter,   and adjusted EBITDA increased $11 million, an 83% increase quarter over quarter, illustrating strong and efficient execution and leverage across our operations. We are confident that these trends will continue through the year and are maintaining our outlook for 2017, which includes 28% growth of contract revenue, 7% growth of organic contract revenue, and double digit earnings growth at the midpoint." Total revenue for the first quarter of 2017 was $163.8 million, an increase of 55%, compared to total revenue of $105.6 million reported in the first quarter of 2016. Total contract revenue for the first quarter of 2017 was $160.2 million, an increase of 56% compared to contract revenue of $102.8 million reported in the first quarter of 2016, and organic contract revenue increased 7%. Contract gross margin was 23% for the first quarter of 2017, consistent with contract gross margin for the first quarter of 2016. Non-GAAP contract gross margin was 27% in the first quarter of 2017, consistent with the first quarter of 2016 and reflects increased gross margin within our Drug Product (DP) business, offset by the addition of Euticals' Fine Chemicals (FC) and API businesses. Recurring royalty revenue in the first quarter of 2017 was $3.6 million, an increase of 31% from $2.7 million in the first quarter of 2016 due primarily to the addition of royalties resulting from our collaboration partner's sales of nitroprusside. Selling, general and administrative (SG&A) expense in the first quarter of 2017 was $33.4 million, up 36% from $24.6 million in the first quarter of 2016. Non-GAAP SG&A expense in the first quarter of 2017 was $27.0 million, up 47% from $18.4 million in the first quarter of 2016, due largely to additional SG&A from the Euticals' acquisition and investments we have made in key support functions. Net loss was $(10.7) million, or $(0.25) per basic and diluted share, in the first quarter of 2017, compared to $(10.1) million, or $(0.29) per basic and diluted share for the first quarter of 2016. Non-GAAP net income in the first quarter was $5.7 million, or $0.13 per diluted share, compared to $2.4 million, or $0.07 per diluted share, for the first quarter of 2016. Adjusted EBITDA in the first quarter of 2017 was $24.0 million, an increase of $11.0 million or 83%, compared to the first quarter of 2016. At March 31, 2017, AMRI had cash and cash equivalents of $35.2 million, compared to $52.0 million at December 31, 2016. During the first quarter of 2017, we used cash of $6.4 million in operating activities primarily due to the timing of payments attributable to severance, employee compensation and benefits and payments to vendors that were primarily incurred and accrued as of December 31, 2016, as well as payments associated with increased inventory levels during the period. These outflows were partially offset by collections from customers during the period. We used cash of $4.1 million in investing activities, primarily attributable to $3.9 million of capital expenditures, and we used cash of $7.2 million in financing activities, primarily related to the principal payments of long-term debt of $4.0 million and net repayments on short-term borrowings of $2.0 million. API contract revenue for the first quarter of 2017 increased 90% compared to the first quarter of 2016, due to $43.4 million of incremental revenue from our Euticals' API business and organic growth. API contract gross margin for the first quarter of 2017 decreased 3 percentage points compared to the first quarter of 2016, primarily due to gross margins attributable to Euticals as compared to our legacy API business. API non-GAAP contract gross margin for the first quarter of 2017 decreased 4 percentage points from the first quarter of 2016 also as a result of lower margins of Euticals' API business as compared to our legacy API business. DDS contract revenue for the first quarter of 2017 increased 24% compared to the first quarter of 2016, due primarily to strong growth in Discovery and Chemical Development. DDS contract gross margin increased 1 percentage point in the first quarter of 2017 as compared to the first quarter of 2016. DDS non-GAAP contract gross margin increased 1 percentage point to 30% in the first quarter of 2017, driven by higher discovery services and chemical development margins. DP contract revenue for the first quarter of 2017 decreased 10% compared to the first quarter of 2016, primarily due to timing of shipments and planned site maintenance activities, partially offset by higher collaboration arrangement revenue. DP contract gross margin and non-GAAP contract gross margin for the first quarter 2017 both increased 9 percentage points compared to the first quarter of 2016, primarily driven by the strong operational performance at the Albuquerque, NM facility. DP royalty revenue in the first quarter of 2017, reflects the addition of royalties resulting from our collaboration partner's sales of nitroprusside, which began in the fourth quarter of 2016. FC is a new reporting segment for AMRI resulting from the acquisition of Euticals in July 2016. Consequently, there are no comparable amounts for the first quarter of 2016. AMRI's guidance takes into account a number of factors, including expected financial results for 2017, anticipated tax rates, foreign currency fluctuations and shares outstanding. AMRI's estimates for full year 2017 are consistent with estimates previously provided on February 21, 2017: AMRI will host a conference call and webcast today at 8:30 a.m. ET to discuss first quarter 2017 results, as well as guidance for 2017. The conference call can be accessed by dialing (866) 208-5728 (domestic calls) or (224) 633-1279 (international calls) at 8:20 a.m. ET and entering passcode 7657377. The webcast and supplementing slides can be accessed on the company's website at www.amriglobal.com. A replay of the conference call can be accessed for 24 hours at (855) 859-2056 (domestic calls) or (404) 537-3406 (international calls) and entering passcode 75749093. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at http://ir.amriglobal.com. About AMRI Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals (FC). For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal). Forward-looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all of the estimates under "Financial Outlook" and statements regarding, among other things, the performance of the Company's previously acquired businesses, the strength of the Company's commercial operations and prospects, projections regarding future revenues and financial performance, and the Company's momentum and long-term growth. The words "outlook", "guidance", "anticipates", "believes", "expects", "may", "plans", "predicts", "will", "potential", "goal" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. The Company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the Company may not be able to predict and may not be within the Company's control. Factors that could cause such differences include, but are not limited to, changes in customers' spending and demand and the trends in pharmaceutical and biotechnology companies' outsourcing of manufacturing services and research and development; the Company's ability to provide quality and timely services and to compete with other companies providing similar services; the Company's ability to comply with strict regulatory requirements; the Company's ability to successfully integrate past and future acquisitions and to realize the expected benefits of each; disruptions in the Company's ability to source raw materials; a change in the Company's relationships with its largest customers; the Company's ability to service its indebtedness; the Company's ability to protect its technology and proprietary information and the confidential information of its customers; the Company's ability to develop products of commercial value under its collaboration arrangements; the risk of patent infringement and other litigation; as well as those risks discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission (SEC) on March 16, 2017, subsequent Quarterly Reports filed with the SEC and the Company's other SEC filings. The financial guidance offered by senior management with respect to 2017 represents a point-in-time estimate and is based on information as of the date of this press release. Senior management has made numerous assumptions in providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those noted above, may cause actual results to differ materially from the guidance provided. The Company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release. Non-GAAP Financial Measures To supplement our financial results prepared in accordance with U.S. GAAP, we have presented non-GAAP measures of contract gross profit, contract gross margin, gross profit, gross margin, SG&A, net income, and earnings per diluted share, adjusted to exclude certain charges (and gains when applicable) that relate to specific events or transactions, such as impairment charges, restructuring charges, executive transition costs, business acquisition costs, realized and unrealized gains and losses on foreign currency transactions related to business acquisitions, and ERP implementation costs. Management typically excludes these amounts when evaluating our operating performance and believes that the resulting non-GAAP measures provide investors with a consistent basis for comparison across periods and, therefore, are useful to investors in assessing our operating performance. Our U.S. GAAP measures are also adjusted to exclude certain non-cash charges (and gains when applicable) such as non-cash debt interest and amortization charges, share-based compensation expense, acquisition accounting inventory adjustments, and acquisition accounting depreciation and amortization for the periods presented for 2017 and 2016. Management typically excludes the amounts described above when evaluating our operating performance and believes that the resulting non-GAAP measures are useful to investors in assessing our operating performance. We have also presented the non-GAAP measure of adjusted EBITDA, which in addition to the items excluded above, further excludes the impact of interest income and expense, depreciation and amortization expense, and income tax expense or benefit. We believe presentation of our non-GAAP measures enhances an overall understanding of our historical financial performance because we believe these measures are an indication of the performance of our base business. Management uses these non-GAAP measures as a basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for the related GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in Tables 1-3. A reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures has been included in Table 4. A reconciliation of organic revenue financial measures to the most directly comparable GAAP financial measures has been included in Table 5. Table 1: Reconciliation of three months ended March 31, 2017 and 2016 contract gross profit and contract gross margin to the non-GAAP financial measures of contract gross profit and non-GAAP contract gross margin. Table 2: Reconciliation of select financial measures to non-GAAP financial measures for the three months ended March 31, 2017 and 2016: Table 3: Reconciliation of the three months ended March 31, 2017 and 2016 net loss to the non-GAAP financial measure of adjusted EBITDA: Table 4:  Reconciliation of forward-looking GAAP financial measures to forward looking non-GAAP financial measures: When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis as that would require estimates for various reconciling items that would be difficult to predict with reasonable accuracy.  For example, it is difficult for the Company to anticipate the need for, or magnitude of, any presently unforeseen one-time restructuring expense or business acquisition costs.  As a result, the Company has prepared the below reconciliation using estimates of reconciling items that are currently expected to be excluded from the non-GAAP financial measures in future periods.  The Company is unable to include all reconciling items at this time without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to variability, complexity and limited visibility to events or conditions in future periods. Table 5: Reconciliation of non-GAAP organic revenue for the three months ended March 31, 2017 and 2016:


News Article | May 9, 2017
Site: marketersmedia.com

AMRI) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 8:30 AM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/23392. The replay will be available online at https://www.investornetwork.com/company/23392. Investor Network (IN) is a new financial content community, serving millions of unique investors market information, earnings, commentary and news on the what's trending. Dedicated to both the professional and the average traders, IN offers timely, trusted and relevant financial information for virtually every investor. IN is an Issuer Direct brand, to learn more or for the latest financial news and market information, visit www.investornetwork.com. Follow us on Twitter @investornetwork.


News Article | May 9, 2017
Site: www.prnewswire.com

Non-GAAP net income, non-GAAP diluted EPS and adjusted EBITDA are non-GAAP financial measures. For a discussion of these measures and reconciliations to U.S. GAAP measures, see "Non-GAAP Financial Measures" and Tables 1, 2 and 3. "We delivered an excellent first quarter, driven by 56 percent growth in contract revenue, 7 percent on an organic basis, including double digit organic growth in our Discovery, Development and Analytical Services (DDS) and Active Pharmaceutical Ingredient (API) businesses," said William S. Marth, AMRI's president and chief executive officer. "GAAP income from operations increased $6 million, a 150% increase quarter over quarter,   and adjusted EBITDA increased $11 million, an 83% increase quarter over quarter, illustrating strong and efficient execution and leverage across our operations. We are confident that these trends will continue through the year and are maintaining our outlook for 2017, which includes 28% growth of contract revenue, 7% growth of organic contract revenue, and double digit earnings growth at the midpoint." Total revenue for the first quarter of 2017 was $163.8 million, an increase of 55%, compared to total revenue of $105.6 million reported in the first quarter of 2016. Total contract revenue for the first quarter of 2017 was $160.2 million, an increase of 56% compared to contract revenue of $102.8 million reported in the first quarter of 2016, and organic contract revenue increased 7%. Contract gross margin was 23% for the first quarter of 2017, consistent with contract gross margin for the first quarter of 2016. Non-GAAP contract gross margin was 27% in the first quarter of 2017, consistent with the first quarter of 2016 and reflects increased gross margin within our Drug Product (DP) business, offset by the addition of Euticals' Fine Chemicals (FC) and API businesses. Recurring royalty revenue in the first quarter of 2017 was $3.6 million, an increase of 31% from $2.7 million in the first quarter of 2016 due primarily to the addition of royalties resulting from our collaboration partner's sales of nitroprusside. Selling, general and administrative (SG&A) expense in the first quarter of 2017 was $33.4 million, up 36% from $24.6 million in the first quarter of 2016. Non-GAAP SG&A expense in the first quarter of 2017 was $27.0 million, up 47% from $18.4 million in the first quarter of 2016, due largely to additional SG&A from the Euticals' acquisition and investments we have made in key support functions. Net loss was $(10.7) million, or $(0.25) per basic and diluted share, in the first quarter of 2017, compared to $(10.1) million, or $(0.29) per basic and diluted share for the first quarter of 2016. Non-GAAP net income in the first quarter was $5.7 million, or $0.13 per diluted share, compared to $2.4 million, or $0.07 per diluted share, for the first quarter of 2016. Adjusted EBITDA in the first quarter of 2017 was $24.0 million, an increase of $11.0 million or 83%, compared to the first quarter of 2016. At March 31, 2017, AMRI had cash and cash equivalents of $35.2 million, compared to $52.0 million at December 31, 2016. During the first quarter of 2017, we used cash of $6.4 million in operating activities primarily due to the timing of payments attributable to severance, employee compensation and benefits and payments to vendors that were primarily incurred and accrued as of December 31, 2016, as well as payments associated with increased inventory levels during the period. These outflows were partially offset by collections from customers during the period. We used cash of $4.1 million in investing activities, primarily attributable to $3.9 million of capital expenditures, and we used cash of $7.2 million in financing activities, primarily related to the principal payments of long-term debt of $4.0 million and net repayments on short-term borrowings of $2.0 million. API contract revenue for the first quarter of 2017 increased 90% compared to the first quarter of 2016, due to $43.4 million of incremental revenue from our Euticals' API business and organic growth. API contract gross margin for the first quarter of 2017 decreased 3 percentage points compared to the first quarter of 2016, primarily due to gross margins attributable to Euticals as compared to our legacy API business. API non-GAAP contract gross margin for the first quarter of 2017 decreased 4 percentage points from the first quarter of 2016 also as a result of lower margins of Euticals' API business as compared to our legacy API business. DDS contract revenue for the first quarter of 2017 increased 24% compared to the first quarter of 2016, due primarily to strong growth in Discovery and Chemical Development. DDS contract gross margin increased 1 percentage point in the first quarter of 2017 as compared to the first quarter of 2016. DDS non-GAAP contract gross margin increased 1 percentage point to 30% in the first quarter of 2017, driven by higher discovery services and chemical development margins. DP contract revenue for the first quarter of 2017 decreased 10% compared to the first quarter of 2016, primarily due to timing of shipments and planned site maintenance activities, partially offset by higher collaboration arrangement revenue. DP contract gross margin and non-GAAP contract gross margin for the first quarter 2017 both increased 9 percentage points compared to the first quarter of 2016, primarily driven by the strong operational performance at the Albuquerque, NM facility. DP royalty revenue in the first quarter of 2017, reflects the addition of royalties resulting from our collaboration partner's sales of nitroprusside, which began in the fourth quarter of 2016. FC is a new reporting segment for AMRI resulting from the acquisition of Euticals in July 2016. Consequently, there are no comparable amounts for the first quarter of 2016. AMRI's guidance takes into account a number of factors, including expected financial results for 2017, anticipated tax rates, foreign currency fluctuations and shares outstanding. AMRI's estimates for full year 2017 are consistent with estimates previously provided on February 21, 2017: AMRI will host a conference call and webcast today at 8:30 a.m. ET to discuss first quarter 2017 results, as well as guidance for 2017. The conference call can be accessed by dialing (866) 208-5728 (domestic calls) or (224) 633-1279 (international calls) at 8:20 a.m. ET and entering passcode 7657377. The webcast and supplementing slides can be accessed on the company's website at www.amriglobal.com. A replay of the conference call can be accessed for 24 hours at (855) 859-2056 (domestic calls) or (404) 537-3406 (international calls) and entering passcode 75749093. Replays of the webcast can also be accessed for up to 90 days after the call via the investor area of the company's website at http://ir.amriglobal.com. About AMRI Albany Molecular Research Inc. (AMRI) is a global contract research and manufacturing organization that has been working with the Life Sciences industry to improve patient outcomes and the quality of life for more than two decades. With locations in North America, Europe and Asia, our key business segments include Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API), Drug Product (DP), and Fine Chemicals (FC). For more information about AMRI, please visit our website at www.amriglobal.com or follow us on Twitter (@amriglobal). Forward-looking Statements This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, all of the estimates under "Financial Outlook" and statements regarding, among other things, the performance of the Company's previously acquired businesses, the strength of the Company's commercial operations and prospects, projections regarding future revenues and financial performance, and the Company's momentum and long-term growth. The words "outlook", "guidance", "anticipates", "believes", "expects", "may", "plans", "predicts", "will", "potential", "goal" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Readers should not place undue reliance on these forward-looking statements. The Company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the Company may not be able to predict and may not be within the Company's control. Factors that could cause such differences include, but are not limited to, changes in customers' spending and demand and the trends in pharmaceutical and biotechnology companies' outsourcing of manufacturing services and research and development; the Company's ability to provide quality and timely services and to compete with other companies providing similar services; the Company's ability to comply with strict regulatory requirements; the Company's ability to successfully integrate past and future acquisitions and to realize the expected benefits of each; disruptions in the Company's ability to source raw materials; a change in the Company's relationships with its largest customers; the Company's ability to service its indebtedness; the Company's ability to protect its technology and proprietary information and the confidential information of its customers; the Company's ability to develop products of commercial value under its collaboration arrangements; the risk of patent infringement and other litigation; as well as those risks discussed in the Company's Annual Report on Form 10-K for the year ended December 31, 2016 as filed with the Securities and Exchange Commission (SEC) on March 16, 2017, subsequent Quarterly Reports filed with the SEC and the Company's other SEC filings. The financial guidance offered by senior management with respect to 2017 represents a point-in-time estimate and is based on information as of the date of this press release. Senior management has made numerous assumptions in providing this guidance which, while believed to be reasonable, may not prove to be accurate. Numerous factors, including those noted above, may cause actual results to differ materially from the guidance provided. The Company expressly disclaims any current intention or obligation to update the guidance provided or any other forward-looking statement in this press release to reflect future events or changes in facts assumed for purposes of providing this guidance or otherwise affecting the forward-looking statements contained in this press release. Non-GAAP Financial Measures To supplement our financial results prepared in accordance with U.S. GAAP, we have presented non-GAAP measures of contract gross profit, contract gross margin, gross profit, gross margin, SG&A, net income, and earnings per diluted share, adjusted to exclude certain charges (and gains when applicable) that relate to specific events or transactions, such as impairment charges, restructuring charges, executive transition costs, business acquisition costs, realized and unrealized gains and losses on foreign currency transactions related to business acquisitions, and ERP implementation costs. Management typically excludes these amounts when evaluating our operating performance and believes that the resulting non-GAAP measures provide investors with a consistent basis for comparison across periods and, therefore, are useful to investors in assessing our operating performance. Our U.S. GAAP measures are also adjusted to exclude certain non-cash charges (and gains when applicable) such as non-cash debt interest and amortization charges, share-based compensation expense, acquisition accounting inventory adjustments, and acquisition accounting depreciation and amortization for the periods presented for 2017 and 2016. Management typically excludes the amounts described above when evaluating our operating performance and believes that the resulting non-GAAP measures are useful to investors in assessing our operating performance. We have also presented the non-GAAP measure of adjusted EBITDA, which in addition to the items excluded above, further excludes the impact of interest income and expense, depreciation and amortization expense, and income tax expense or benefit. We believe presentation of our non-GAAP measures enhances an overall understanding of our historical financial performance because we believe these measures are an indication of the performance of our base business. Management uses these non-GAAP measures as a basis for evaluating our financial performance as well as for budgeting and forecasting of future periods. For these reasons, we believe they can be useful to investors. The presentation of this additional information should not be considered in isolation or as a substitute for the related GAAP measures. Reconciliations of these non-GAAP measures to the most directly comparable GAAP financial measures are set forth in Tables 1-3. A reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP financial measures has been included in Table 4. A reconciliation of organic revenue financial measures to the most directly comparable GAAP financial measures has been included in Table 5. Table 1: Reconciliation of three months ended March 31, 2017 and 2016 contract gross profit and contract gross margin to the non-GAAP financial measures of contract gross profit and non-GAAP contract gross margin. Table 2: Reconciliation of select financial measures to non-GAAP financial measures for the three months ended March 31, 2017 and 2016: Table 3: Reconciliation of the three months ended March 31, 2017 and 2016 net loss to the non-GAAP financial measure of adjusted EBITDA: Table 4:  Reconciliation of forward-looking GAAP financial measures to forward looking non-GAAP financial measures: When planning, forecasting and analyzing future periods, the Company does so primarily on a non-GAAP basis without preparing a GAAP analysis as that would require estimates for various reconciling items that would be difficult to predict with reasonable accuracy.  For example, it is difficult for the Company to anticipate the need for, or magnitude of, any presently unforeseen one-time restructuring expense or business acquisition costs.  As a result, the Company has prepared the below reconciliation using estimates of reconciling items that are currently expected to be excluded from the non-GAAP financial measures in future periods.  The Company is unable to include all reconciling items at this time without unreasonable effort due to the unavailability of the information needed to calculate reconciling items and due to variability, complexity and limited visibility to events or conditions in future periods. Table 5: Reconciliation of non-GAAP organic revenue for the three months ended March 31, 2017 and 2016: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/amri-announces-first-quarter-2017-results-300453724.html


News Article | May 16, 2017
Site: globenewswire.com

Dublin, May 16, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Lyophilization Services for Biopharmaceuticals, 2017-2027" report to their offering. The Lyophilization Services for Biopharmaceuticals, 2017-2027' report provides an extensive study on the current market landscape of lyophilization services for biopharmaceuticals. The study presents an in-depth analysis of a diverse set of companies that provide such services across different regions worldwide. In fact, we identified close to 90 companies that are actively involved in providing lyophilization services for biopharmaceuticals. The study features a detailed analysis of the existing size and potential future growth opportunities (2017-2027) in the lyophilization services market for biopharmaceuticals. We have provided insights on the likely regional evolution of the market covering North America, Europe (UK, France, Italy, Spain, Germany and rest of Europe), Asia Pacific (Japan, China, India and South Korea) and rest of the world. In addition, we have provided the likely evolution and a market attractiveness analysis on the basis of the type of containment system (bulk containers, vials, syringes, ampoules and cartridges). In order to account for the uncertainties associated with some of the key parameters and to add robustness to our model, we have presented three different forecast scenarios, depicting conservative, base and optimistic tracks of the market's evolution. The research, analysis and insights presented in this report are backed by a deep understanding of key insights gathered from both secondary and primary research. Actual figures have been sourced and analyzed from publicly available data. For the purpose of the study, we invited over 80 stakeholders to participate in a survey to solicit their opinions on upcoming opportunities, challenges and likely future trends. The opinions and insights presented in this study were also influenced by discussions conducted with experts in this field. These included contributions from Steven Nail (Principal Scientist, Baxter BioPharma Solutions), Adam Viverette (Lyophilization Manager, Patheon), Patrick DePalma (Director, CMO Business Development, BioDefense Division, Emergent BioSolutions) and John Shaw (Head of Business Development and Marketing, Vibalogics). Key Topics Covered: 1. PREFACE 1.1. Scope of the Report 1.2. Research Methodology 1.3. Chapter Outlines 2. EXECUTIVE SUMMARY 3. INTRODUCTION TO LYOPHILIZATION 3.1. Chapter Overview 3.2. Lyophilization: Historical Background 3.3. Lyophilization: Underlying Principle 3.4. Lyophilization: Equipment 3.5. Lyophilization: Advantages and Disadvantages 3.6. Lyophilization: Applications 4. LYOPHILIZATION OF BIOPHARMACEUTICALS 4.1. Chapter Overview 4.2. Need for Lyophilization of Biopharmaceuticals 4.3. Lyophilization Process for Biopharmaceuticals 4.4. Lyophilization Cycle Development and Optimization 4.5. Containment Systems Used for the Lyophilization of Biopharmaceuticals 5. COMPETITIVE LANDSCAPE 5.1. Chapter Overview 5.2. Lyophilization Service Providers for Biopharmaceuticals: Overall Landscape 5.3. Lyophilization Service Providers for Biopharmaceuticals: Analysis by Type of Biopharmaceuticals Lyophilized 5.4. Lyophilization Service Provides for Biopharmaceuticals: Analysis by Scale of Operation 5.5. Lyophilization Service Providers for Biopharmaceuticals: Analysis by Containment Systems 6. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: NORTH AMERICA 6.1. Chapter Overview 6.2. Anteco Pharma 6.3. Axcellerate Pharma 6.4. Berkshire Sterile Manufacturing 6.5. Emergent BioSolutions 6.6. LSNE Contract Manufacturing 6.7. Lyophilization Technology 6.8. Quality BioResources 6.9. North America: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 7. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: EUROPE 7.1. Chapter Overview 7.2. Amatsigroup 7.3. Biopharma Technology 7.4. Boehringer Ingelheim BioXcellence 7.5. LYOCONTRACT 7.6. Lyofal 7.7. Vetter Pharma 7.8. Europe: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 8. LYOPHILIZATION SERVICE PROVIDERS FOR BIOPHARMACEUTICALS: ASIA PACIFIC 8.1. Chapter Overview 8.2. BioZed Engineering 8.3. Bovogen Biologics 8.4. CinnaGen 8.5. Mycenax Biotech 8.6. Piramal Pharma Solutions 8.7. Samsung Biologics 8.8. Siam Bioscience 8.9. WuXi AppTec 8.10. Asia Pacific: Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 8.10.1. Asia Pacific Lyophilization Services Market for Biopharmaceuticals: Distribution by Type of Containment System (USD Million) 9. MARKET SIZING AND FORECAST 9.1. Chapter Overview 9.2. Forecast Methodology 9.3. Lyophilization Services Market for Biopharmaceuticals, 2017-2027 (USD Million) 9.4. Lyophilization Services Market for Biopharmaceuticals, 2017-2027: Distribution by Region (USD Million) 9.5. Lyophilization Services Market for Biopharmaceuticals, 2017-2027: Distribution by Type of Containment System (USD Million) 10. BENCHMARK ANALYSIS 10.1. Chapter Overview 10.2. Benchmark Analysis: Methodology 10.3. Benchmark Analysis: Peer Groups 11. LYOPHILIZATION CYCLE DEVELOPMENT AND OPTIMIZATION 11.1. Chapter Overview 11.2. Lyophilization Cycle Development 11.3. Lyophilization Cycle Optimization 11.4. Lyophilization Cycle Development and Optimization: Service Providers 11.5. Lyophilization Cycle Development and Optimization Service Providers: Company Snapshots 12. ALTERNATIVE APPROACHES TO LYOPHILIZATION 12.1. Chapter Overview 12.2. Spray Drying 12.3. Spray Freeze Drying 12.4. Atmospheric Spray Freeze Drying 12.5. Vacuum Foam Drying 13. SURVEY ANALYSIS 13.1. Chapter Overview 13.2. Seniority Level of Respondents 13.3. Type of Biopharmaceuticals Lyophilized 13.4. Type of Containment System 13.5. Scale of Operation 13.6. Lyophilization Cycle Development and Optimization 13.7. Location of Lyophilization Facility 13.8. Likely Market Size 14. CONCLUSION 14.1. In Light of High Costs Associated with Establishing In-house Lyophilization Capabilities, Outsourcing has Emerged as a Convenient Alternative 14.2. Cycle Development and Optimization are Among the Key Lyophilization Processes; a Number of Players Specializing in These Services Have Entered the Market Expanding the Value Chain 14.3. Although Alternative Methods have Gained Attention in Recent Times, Lyophilization will Continue to Play a Pivotal Role 14.4. Fueled by the Growing Pipeline of Biopharmaceuticals, the Market is Likely to Witness Continuous Growth in the Coming Decade 15. INTERVIEW TRANSCRIPTS 15.1. Chapter Overview 15.2. Steven Nail, Principal Scientist, Baxter BioPharma Solutions 15.3. Adam Viverette, Lyophilization Manager, Patheon 15.4. Patrick DePalma, Director, CMO Business Development BioDefense Division, Emergent BioSolutions 15.5. John Shaw, Head of Business Development and Marketing, Vibalogics Companies Mentioned - AB BioTechnologies - Affinity Biologicals - Affinity Life Sciences - Ajinomoto - Albany Molecular Research (AMRI) - Alcami - Althea - Amatsigroup - Anteco Pharma - Apexigen - Aptevo Therapeutics - AusiaBio - Avrio Biopharmaceuticals - Axcellerate Pharma - Axys-Network - BSP Pharmaceuticals - Baccinex - Baxter BioPharma Solutions - Bayer Healthcare - Berkshire Sterile Manufacturing (BSM) - BioConnection - BioReliance - BioTechLogic - BioTechnique - BioZed Engineering - Biocon - Biopharma Technology - Bioserv Corporation - Biotechpharma - Biovian - Boehringer Ingelheim BioXcellence - Bovogen Biologicals - Bryllan - Burrard Pharmaceuticals - CARBOGEN AMCIS - CEPiA - CMC Biologics - Camurus - Canada Peptide - Capua BioServices - Catalent - Cenexi - CinnaGen - Clarity BioSolutions - Cobra Biologics - Coldstream Laboratories - Cook Pharmica - Corden Pharma - Coriolis Pharma - CuriRx - Dalton Pharma Services - DavosPharma - EUCODIS Bioscience - Emergent BioSolutions - Engineered Biopharmaceuticals - Eurogentec - FUJIFILM Diosynth Biotechnologies - Famar Health Care Services - Fedegari Group - Formurex - Fresenius Kabi Product Partnering - Frontage Labs - GILYOS (GIeseler LYOphilization Solutions) - GP Pharm - Gipharma - GlaxoSmithKline (GSK) - Goodwin Biotechnology - Grand River Aseptic Manufacturing (GRAM) - HALIX - HTD Biosystems - Hart Biologicals - Hovione - Hycult Biotech - IDIFARMA - IDT Biologika - Infectious Disease Research Institute (IDRI) - Integrity Bio - Jubilant HollisterStier - Jubilant Pharma - KABS Pharmaceutical Services - KBI Biopharma - Kamat Pharmatech - Kemwell Biopharma - LEUKOCARE - LSNE Contract Manufacturing - LYOCONTRACT - Legacy BioDesign - Lonza - Lyofal - Lyophilization Technology - MabPlex - Markt Technologies - MassDevelopment - Medicago - Micro-sphere - Miltenyi Biotec - Mycenax Biotech - NanoTools - National Institute of Allergy and Infectious Diseases (NIAID) - Nitto Avecia Pharma Services - Nova Laboratories - OctoPlus - Oncotec Pharma Produktion - OsoBio - PREMAS Biotech - PYRAMID Laboratories - PaizaBio - Particle Sciences - Patheon - Pfizer CentreOne - Pharmagen - Pharmatek - Pierre Fabre - Piramal Pharma Solutions - Praxair - Praxis Pharmaceutical - ProJect Pharmaceutics - Quality BioResources - Recipharm - Rentschler - SGS Group - SP Scientific - SYNERLAB Group - Samsung Biologics - Sanofi - Siam Bioscience - Singota Solutions - StemProtein - Symbiosis Pharmaceutical Services - SynCo Bio Partners - Syngene - The Native Antigen Company (NAC) - Therapure Biomanufacturing - Tofflon - Universal Stabilization Technologies - Upperton - Vectura - Vetter Pharma - Vibalogics - VxP Pharma - Wolfe Laboratories - WuXi AppTec For more information about this report visit http://www.researchandmarkets.com/research/46rmjf/lyophilization

Loading AMRI collaborators
Loading AMRI collaborators